Difference between revisions of "Fruquintinib (Elunate)"
Jump to navigation
Jump to search
m |
m |
||
| Line 14: | Line 14: | ||
[[Category:VEGFR inhibitors]] | [[Category:VEGFR inhibitors]] | ||
| − | [[Category:Colorectal cancer medications]] | + | [[Category:Colorectal cancer medications (investigational)]] |
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Revision as of 00:30, 30 April 2022
Mechanism of action
VEGFR inhibitor
Preliminary data
Colon cancer
- FRESCO: Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H, Pan H, Guo W, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, Wu C, Cheng Y, Chen D, Li W, Sun S, Yu Z, Cao P, Chen H, Wang J, Wang S, Wang H, Fan S, Hua Y, Su W. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018 Jun 26;319(24):2486-2496. link to original article PubMed
Also known as
- Code name: HMPL-013